Tech Company Financing Transactions

Sensei Biotherapeutics Funding Round

On 1/12/2021, Sensei Biotherapeutics raised $30 million in Series B investment from Apeiron Investment Group, Catalio Capital Management and Cambrian Biopharma.

Transaction Overview

Company Name
Sensei Biotherapeutics
Announced On
1/12/2021
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors

Apeiron Investment Group (Lead Investor) (Christian Angermayer)

Catalio Capital Management (Lead Investor) (George Petrocheilos)

Cambrian Biopharma

Future Ventures

Moore Strategic Ventures

Presight Capital

Pura Vida Investments

Proceeds Purpose
Proceeds support advancement of lead product candidate and next-generation platform for personalized yet off-the-shelf cancer immunotherapies.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1405 Research Blvd. 125
Rockville, MD 20850
USA
Phone
(240) 243-8000
Website
www.senseibio.com
Email Address
[email protected]
Overview
Sensei Biotherapeutics is a clinical-stage biotechnology company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. Driven by innovative science, world class scientists, and an entrepreneurial culture.
Profile
Sensei Biotherapeutics LinkedIn Company Profile
Social Media
Sensei Biotherapeutics Company Twitter Account
Company News
Sensei Biotherapeutics News
Facebook
Sensei Biotherapeutics on Facebook
YouTube
Sensei Biotherapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
John Celebi
  John Celebi LinkedIn Profile  John Celebi Twitter Account  John Celebi News  John Celebi on Facebook
Chief Medical Officer
Marie Fjaellskog
  Marie Fjaellskog LinkedIn Profile  Marie Fjaellskog Twitter Account  Marie Fjaellskog News  Marie Fjaellskog on Facebook
Chief Scientific Officer
Robert Pierce
  Robert Pierce LinkedIn Profile  Robert Pierce Twitter Account  Robert Pierce News  Robert Pierce on Facebook
Vice President
Jean Campbell
  Jean Campbell LinkedIn Profile  Jean Campbell Twitter Account  Jean Campbell News  Jean Campbell on Facebook
Vice President
Edward van der Horst
  Edward van der Horst LinkedIn Profile  Edward van der Horst Twitter Account  Edward van der Horst News  Edward van der Horst on Facebook
VP - Finance
Erin Colgan
  Erin Colgan LinkedIn Profile  Erin Colgan Twitter Account  Erin Colgan News  Erin Colgan on Facebook
VP - Operations
Pauline Callinan
  Pauline Callinan LinkedIn Profile  Pauline Callinan Twitter Account  Pauline Callinan News  Pauline Callinan on Facebook
VP - Operations
Alice Drumheller
  Alice Drumheller LinkedIn Profile  Alice Drumheller Twitter Account  Alice Drumheller News  Alice Drumheller on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/12/2021: Bolt Technology venture capital transaction
Next: 1/12/2021: Atalanta Therapeutics venture capital transaction

 

Share this article

 

Where The Data Comes From

We record every notable VC transaction. VC transactions reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.